Fig. 4From: Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trialOverall survival. The overall survival analysis included all patients who died during the study or during long-term follow-up after discontinuation of study treatment. HR, hazard ratioBack to article page